2026-08-25

ASN — Yellow Cat Drilling Confirms Mineralisation Along Strike

ASN's Phase 1 drilling successfully mapped a 2.5 km mineralized trend connecting two historical uranium-vanadium deposits, with peak assays (774 ppm U) indicating 'extreme proximity' to ore-grade zones per USGS thresholds. Phase 2 will focus on JORC 2012 resource definition of a deeper western historical resource with higher-grade, unoxidized material below the water table.

💰 Peak uranium intercept: 774 ppm U (1 ft) · Mineralized zone thickness: >14 ft (mined out stope) · Strike continuity confirmed: 2,500 m between McCoy & Cactus Rat · Exploration program scale: 23 holes, 1,667 ft

Materiality: Exploration confirmation with no new resource estimate; Phase 2 drilling underway (enviro/cultural surveys commenced). Cash position ($4.1m) adequate for near-term drilling but limited runway; result de-risks western target for JORC upgrade.

Priced in? Stock +7% over 20d and +2% over 5d into announcement; modest pre-run suggests market was cautious—result validates continuity thesis but grade threshold (774 ppm) below immediate ore-grade (>1,000 ppm) may explain muted reaction.

high-confidence read, materiality quantified

NEU — European Commission grants marketing authorisation for DAYBU

DAYBU becomes first and only approved treatment for Rett syndrome across 30 EU territories, unlocking $35m upfront and up to $170m in tiered milestones plus royalties through partner Acadia. This is a material regulatory de-risking event that validates trofinetide's commercial potential outside the US, though NEU is dependent on Acadia's execution and EU reimbursement dynamics.

💰 EU Marketing Authorization: DAYBU (trofinetide) approved for Rett syndrome · Upfront Payment: $35 million upon first commercial sale · Milestone Payments: Up to $170 million on escalating annual sales thresholds · Royalty Rate: Mid-teens to low-20s % of net sales

Materiality: Upfront ($35m) and milestones (up to $170m) represent meaningful future cash inflow relative to $2.8b market cap; upfront alone ~1.2% of market cap, though contingent on Acadia's commercial success and reimbursement.

Priced in? Stock +34% over 20d into announcement; -2% over final 5d suggests market had priced in a favorable outcome or timing; limited downside surprise, but EU approval removes regulatory risk.

high-confidence read, materiality quantified

OD6 · $40M — HORSESHOE CHANNEL RE-ASSAYS CONFIRM MATERIALLY HIGHER GRADE

Re-assaying with correct laboratory technique (F-XRF24 vs. prior F-ELE82) confirms Horseshoe channel grades were materially under-reported, with standout zones of 50–85% CaF₂ over 15–50m widths from surface—exceptional for global fluorspar context. Mineralisation remains open and the company is now focused on proving scale through drilling and metallurgical optimization ahead of potential production.

💰 SE Wall: 50m @ 79.3% CaF₂ · Central Bench: 15m @ 85.8% CaF₂ · NW Wall: 22m @ 78.8% CaF₂ · Average uplift: 12.9% CaF₂

Materiality: Grade uplift ~13% average across a surface-exposed 80m-wide zone with 15–30m thickness; combined with prior metallurgical samples, this substantially strengthens resource narrative at $40m market cap; cash runway (~6–9 months at current spend) implies near-term capital requirement likely

Priced in? Stock +35% over 20 days and +8% over 5 days into this result; market has front-run the re-assay announcement, suggesting expectations were broadly anticipated but confirmation of material uplift validates the momentum

🏔 ~150km near EVG.AX ($18M — 0.46× subject cap)

high-confidence read, materiality quantified

XPN — Appendix 4E and FY26 Annual Report

XPN executed a portfolio streamlining in FY26, divesting non-core assets (Alpha Digital, GMP/GCP) while growing core Wondaris AI platform revenue 38% to $12.3m and flipping to positive EBITDA of $1.1m. The pending $5.5m Datisan sale will materially boost an already tight balance sheet, effectively doubling cash reserves and positioning the company for M&A or accelerated product development in FY27.

💰 FY26 Revenue: $12.3m (+38% YoY) · Statutory EBITDA: $1.1m (vs -$0.1m FY25) · Net Profit after Tax: $0.2m (vs -$1.4m FY25) · Cash at bank: $2.79m

Materiality: Datisan transaction ($5.5m cash) represents ~110% of current market cap and ~2x current cash position; revenue growth and EBITDA inflection constitute a structural turnaround for a $5m-cap company previously loss-making.

Priced in? Minimal 20d run-up (+5%); both divestitures announced mid-June 2026 separately; annual report validates execution on cost discipline and cash generation but limited new catalysts disclosed beyond FY27 M&A targets.

high-confidence read, materiality quantified